American journal of therapeutics · 2026
Psychedelic Therapy: A Primer for Primary Care Clinicians-5-Methoxy-N,N-Dimethyltryptamine.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tabaac Burton J, Shinozuka Kenneth, Weisman Anne, Chaudhry Shiven, Seynaeve Mathieu, Muir Owen S
Аннотация
BACKGROUND: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), also officially known as mebufotenin, is a naturally occurring serotonergic psychedelic alkaloid found in the venom of the Sonoran Desert toad ( Incilius alvarius ) and various plant species.
AREAS OF UNCERTAINTY: Trace levels of 5-MeO-DMT may be produced endogenously in humans, but its physiologic role remains unclear. Safety profiles indicate low risk in controlled settings, though longer-term follow-ups with human subjects may be needed. Phenomenological overlaps with near-death experiences are noted but debated.
THERAPEUTIC ADVANCES: Clinical trials have demonstrated rapid antidepressant effects. Top-line data from a recent phase 2b trial showed that 57.5% of participants remitted from treatment-resistant depression within 8 days. Other phase 2a and 2b trials have provided further, though still preliminary, evidence that 5-MeO-DMT may reduce depressive symptoms more than existing pharmacologic treatments, like selective serotonin reuptake inhibitors.
LIMITATIONS: Most studies are early phase with small samples (n ≤193). Only 2 double-blind randomized controlled trials (RCTs) have been conducted in clinical populations, and long-term effects require further investigation.
CONCLUSIONS: Emerging evidence supports 5-MeO-DMT as a promising, ultra-short-acting psychedelic for treatment-resistant depression and other psychiatric conditions, warranting larger RCTs.
AREAS OF UNCERTAINTY: Trace levels of 5-MeO-DMT may be produced endogenously in humans, but its physiologic role remains unclear. Safety profiles indicate low risk in controlled settings, though longer-term follow-ups with human subjects may be needed. Phenomenological overlaps with near-death experiences are noted but debated.
THERAPEUTIC ADVANCES: Clinical trials have demonstrated rapid antidepressant effects. Top-line data from a recent phase 2b trial showed that 57.5% of participants remitted from treatment-resistant depression within 8 days. Other phase 2a and 2b trials have provided further, though still preliminary, evidence that 5-MeO-DMT may reduce depressive symptoms more than existing pharmacologic treatments, like selective serotonin reuptake inhibitors.
LIMITATIONS: Most studies are early phase with small samples (n ≤193). Only 2 double-blind randomized controlled trials (RCTs) have been conducted in clinical populations, and long-term effects require further investigation.
CONCLUSIONS: Emerging evidence supports 5-MeO-DMT as a promising, ultra-short-acting psychedelic for treatment-resistant depression and other psychiatric conditions, warranting larger RCTs.